TNXP Tonix Pharmaceuticals Holding Corporation

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * LEDERMAN SETH	2. Issuer Name and Ticker or Trading Symbol Tonix Pharmaceuticals Holding Corp. [ TNXP ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) Chief Executive Officer
(Last)          (First)          (Middle) C/O TONIX PHARMACEUTICALS HOLDING CORP, 26 MAIN STREET, SUITE 101	3. Date of Earliest Transaction (MM/DD/YYYY) 9/28/2021
(Street) CHATHAM, NJ 07928 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.001 par value	9/28/2021		P		12000	A	$0.61	12177	D
Common Stock, $0.001 par value								135000	I	By 401(k) plan
Common Stock, $0.001 par value								459	I	By IRA Account
Common Stock, $0.001 par value								31	I	By spouse
Common Stock, $0.001 par value								30	I	By Leder Laboratories, Inc. (1)
Common Stock, $0.001 par value								30	I	By Starling Pharmaceuticals, Inc. (1)
Common Stock, $0.001 par value								205	I	By Lederman & Co., LLC (1)
Common Stock, $0.001 par value								33	I	By L&L Technologies, LLC (1)
Common Stock, $0.001 par value								59	I	By Targent Pharmaceuticals, LLC (1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:
(1)	Reporting person may be deemed to be a control person of this entity.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
LEDERMAN SETH C/O TONIX PHARMACEUTICALS HOLDING CORP 26 MAIN STREET, SUITE 101 CHATHAM, NJ 07928	X		Chief Executive Officer

Signatures
/s/ Seth Lederman		9/28/2021
**Signature of Reporting Person		Date